TY - JOUR
TI - COVID-19 and antiphospholipid antibodies: A position statement and
management guidance from AntiPhospholipid Syndrome Alliance for Clinical
Trials and InternatiOnal Networking (APS ACTION)
AU - Wang, Xin
AU - Gkrouzman, Elena
AU - Andrade, Danieli Castro Oliveira and
AU - Andreoli, Laura
AU - Barbhaiya, Medha
AU - Belmont, H. Michael
AU - Branch,
AU - David Ware
AU - de Jesus, Guilherme R.
AU - Efthymiou, Maria and
AU - Rios-Garces, Roberto
AU - Gerosa, Maria
AU - El Hasbani, Georges and
AU - Knight, Jason
AU - Meroni, Pier Luigi
AU - Pazzola, Giulia
AU - Petri,
AU - Michelle
AU - Rand, Jacob
AU - Salmon, Jane
AU - Tektonidou, Maria and
AU - Tincani, Angela
AU - Uthman, Imad W.
AU - Zuily, Stephane
AU - Zuo, Yu and
AU - Lockshin, Michael
AU - Cohen, Hannah
AU - Erkan, Doruk
AU - APS ACTION
JO - Lupus Science and Medicine
PY - 2021
VL - 30
TODO - 14
SP - 2276-2285
PB - SAGE Publications Ltd
SN - null
TODO - 10.1177/09612033211062523
TODO - Antiphospholipid antibodies; antiphospholipid syndrome; lupus
anticoagulant; Hughes syndrome; thrombosis; anticoagulation; COVID-19
TODO - Coronavirus disease 2019 (COVID-19) is associated with a high rate of
thrombosis. Prolonged activated partial thromboplastin times (aPTT) and
antiphospholipid antibodies (aPL) are reported in COVID-19 patients. The
majority of publications have not reported whether patients develop
clinically relevant persistent aPL, and the clinical significance of new
aPL-positivity in COVID-19 is currently unknown. However, the reports of
aPL-positivity in COVID-19 raised the question whether common mechanisms
exist in the pathogenesis of COVID-19 and antiphospholipid syndrome
(APS). In both conditions, thrombotic microangiopathy resulting in
microvascular injury and thrombosis is hypothesized to occur through
multiple pathways, including endothelial damage, complement activation,
and release of neutrophil extracellular traps (NETosis). APS-ACTION, an
international APS research network, created a COVID-19 working group
that reviewed common mechanisms, positive aPL tests in COVID-19
patients, and implications of COVID-19 infection for patients with known
aPL positivity or APS, with the goals of proposing guidance for clinical
management and monitoring of aPL-positive COVID-19 patients. This
guidance also serves as a call and focus for clinical and basic
scientific research.
ER -